Drug intelligence / Profile preview

Prismasol

Development stage
Approved
Lead developer
Takeda
Modality
Small Molecules
Administration
Parenteral
01

Overview

Prismasol is a sterile, pre-mixed electrolyte and bicarbonate solution used as a replacement fluid or dialysate in Continuous Renal Replacement Therapy (CRRT). Developed by Baxter (and managed by its kidney care spinoff, Vantive Health), it is indicated for pediatric and adult patients to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. It is also used in cases of drug poisoning to facilitate the removal of dialyzable substances. The solution typically comes in a dual-chamber bag containing electrolytes such as sodium, calcium, magnesium, potassium, and chloride, along with a bicarbonate buffer and sometimes glucose. These components are mixed immediately before administration to the extracorporeal circuit to maintain physiological homeostasis in critically ill patients with acute kidney injury.

Brand names
PrismasolPrismasol 2Prismasol2Prismasol-2
Other names
CRRT replacement solution
02

Targets

ClC (CLC chloride channel family)

Beyond the preview

Go deeper on Prismasol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prismasol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call